UPDATE : Monday, June 24, 2019
상단여백
Despite regulator’s ruling delay, Kolon TissueGene likely to be reviewed for delisting
The stock market regulator said it has pushed back the deadline to decide w...
by Jeong Sae-im  |  2019-06-20 14:20
라인
294 shareholders file suit against Kolon TissueGene for damage compensation
Kolon TissueGene said in a public filing on Thursday that its 294 minority ...
by Jeong Sae-im  |  2019-06-14 10:51
라인
Celltrion unveils P3 trial results for rheumatoid biosimilar in Europe
Celltrion has presented the phase 3 clinical trial result for Remsima SC, t...
by Lee Han-soo  |  2019-06-13 16:10
라인
Kolon TissueGene CEO resigns
Kolon TissueGene, a subsidiary of Kolon Life Science, said Co-CEO Lee Woo-s...
by Jeong Sae-im  |  2019-06-07 15:35
라인
[ASCO 2019] ‘Ontruzant demonstrates equal quality to original drug’
CHICAGO, Ill. -- Samsung Bioepis has proved its quality control ability, as...
by Lee Han-soo, KBR correspondent  |  2019-06-04 14:17
라인
Kolon’s minority shareholders demand over ₩25 billion in damage
Minority shareholders of Kolon Life Science and its subsidiary Kolon Tissue...
by Jeong Sae-im  |  2019-06-03 14:53
라인
Invossa inventor sold Kolon shares at highest value
Former Kolon TissueGene CEO Lee Kwan-hee, the inventor of now-suspended gen...
by Jeong Sae-im  |  2019-06-03 14:52
라인
Until when will Kolon keep lying about Invossa?
Kolon Life Science’s “explanations” about the mislabeling of the cell ingre...
by Jeong Sae-im  |  2019-05-31 14:59
라인
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug
Samsung BioLogics said it has signed a deal with U.S. biotech firm CytoDyn ...
by Jeong Sae-im  |  2019-05-31 14:59
라인
Announcement of Invossa license revocation was ‘procedural breach’: Kolon
The government’s recent announcement that it would nullify the license of I...
by Jeong Sae-im  |  2019-05-30 13:28
라인
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy
Oncology researchers around the world are paying keen attention to MDM2 (mo...
by Kim Yun-mi  |  2019-05-29 12:35
라인
Invossa poses almost no safety threat: regulator
The Ministry of Food and Drug Safety said there was no significant concern ...
by Lee Hye-seon  |  2019-05-28 16:02
라인
Brazil OKs Samsung Bioepis’ trastuzumab biosimilar
Brazil’s Agencia Nacional de Vigilancia Sanitaria has granted marketing aut...
by Lee Han-soo  |  2019-05-27 15:52
라인
‘Shareholders can surely win lawsuit against Kolon’
Law firm Hankyul is pursuing a lawsuit against Kolon Life Science and Kolon...
by Jeong Sae-im  |  2019-05-24 19:34
라인
‘Kolon’s extra data insufficient to explain Invossa mislabeling’
The Ministry of Food and Drug Safety said additional material submitted by ...
by Lee Hye-seon  |  2019-05-23 14:51
라인
Prosecutors seek arrest warrant of Samsung BioLogics CEO
The Seoul Central District Prosecutors Office is seeking an arrest warrant ...
by Lee Han-soo  |  2019-05-23 11:19
라인
[News Focus] Kolon, regulator rapped for not doing enough to quell concerns of patients
More than 50 days have passed since the Ministry of Food and Drug Safety (M...
by Jeong Sae-im  |  2019-05-22 11:59
라인
Legislator, activists call for revoking Invossa license, conducting probes
A lawmaker and civic groups urged the government to nullify the license of ...
by Jeong Sae-im  |  2019-05-21 16:03
라인
Kolon to follow 3,700 Invossa-treated patients for 15 years
Kolon Life Science said it would conduct a long-term follow-up study on ove...
by Jeong Sae-im  |  2019-05-17 15:38
라인
Will Celltrion CEO’s bet on ‘bio valley’ pay off?
“It’s been 19 years since I started this business. The first decade was a t...
by Jeong Sae-im  |  2019-05-17 13:21
여백
여백
여백
Back to Top